mProX™ Human FCGR2B Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

FCGR2B, also known as Fc fragment of IgG low affinity IIb receptor, has been implicated in various diseases and conditions. In Parkinson's disease, FCGR2B has been identified as one of the potential causal genes and a genetically supported drug target. It has been found to play a robust causal role for Parkinson's disease at the protein level in blood, cerebrospinal fluid, and brain. In carotid atherosclerosis, FCGR2B has been identified as a potential biomarker, with higher expression associated with worse prognosis. In spinal cord injury-induced immunodeficiency, FCGR2B is part of the complex neuroendocrine regulatory networks and is involved in the immune response. In gliomas, FCGR2B has been identified as a prognostic marker and is associated with the immune microenvironment. It may play an important role in the occurrence, development, and invasion of tumors by influencing the tumor microenvironment of immunosuppression. Additionally, FCGR2B expressed on CD8+ T cells has been found to limit responsiveness to PD-1 checkpoint inhibition in cancer, suggesting its involvement in modulating antitumor immune responses. Overall, FCGR2B has diverse applications in different disease contexts, including Parkinson's disease, carotid atherosclerosis, spinal cord injury-induced immunodeficiency, gliomas, and cancer immunotherapy.